NASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis → Stock-Picking AI Predicts #1 Stock of 2024 (From Altimetry) (Ad) Free LUNG Stock Alerts $9.82 +0.44 (+4.69%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$9.55▼$9.8950-Day Range$7.28▼$10.3952-Week Range$7.11▼$14.84Volume999,827 shsAverage Volume562,070 shsMarket Capitalization$378.46 millionP/E RatioN/ADividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Pulmonx alerts: Email Address Pulmonx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside66.3% Upside$16.33 Price TargetShort InterestHealthy4.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 15 Articles This WeekInsider TradingSelling Shares$469,012 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.14 out of 5 starsMedical Sector332nd out of 904 stocksSurgical & Medical Instruments Industry44th out of 96 stocks 4.4 Analyst's Opinion Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePulmonx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.95% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmonx has recently increased by 53.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUNG. Previous Next 2.4 News and Social Media Coverage News SentimentPulmonx has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Pulmonx this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for LUNG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Pulmonx to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $469,012.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pulmonx are expected to remain at ($1.63) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -6.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -6.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryStock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.Click here to learn what's coming (and how to prepare). About Pulmonx Stock (NASDAQ:LUNG)Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Read More LUNG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUNG Stock News HeadlinesMay 4, 2024 | finance.yahoo.comEarnings Update: Pulmonx Corporation (NASDAQ:LUNG) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsMay 3, 2024 | finance.yahoo.comPulmonx First Quarter 2024 Earnings: Beats ExpectationsMay 5, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.May 3, 2024 | finance.yahoo.comPulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comAnalyst Recommendation Report Summary: Insights and Strategic Investment PerspectivesMay 2, 2024 | marketwatch.comPulmonx Surge After Strong 1Q PerformanceMay 2, 2024 | finance.yahoo.comQ1 2024 Pulmonx Corp Earnings CallMay 2, 2024 | finance.yahoo.comPulmonx Corp (LUNG) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...May 5, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.May 1, 2024 | investorplace.comLUNG Stock Earnings: Pulmonx Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comPulmonx Corp (LUNG) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Continued LossesMay 1, 2024 | globenewswire.comPulmonx Reports First Quarter 2024 Financial ResultsApril 25, 2024 | finance.yahoo.comPulmonx Corporation (LUNG) Stock Price, News, Quote & History - Yahoo FinanceApril 10, 2024 | globenewswire.comPulmonx to Report First Quarter 2024 Financial Results on May 1, 2024April 4, 2024 | investing.comPulmonx names new CFO to bolster financial leadershipApril 3, 2024 | markets.businessinsider.comNavigating 6 Analyst Ratings For PulmonxApril 2, 2024 | marketwatch.comPulmonx Taps Mehul Joshi as Finance ChiefApril 2, 2024 | globenewswire.comPulmonx Announces Appointment of Mehul Joshi as Chief Financial OfficerMarch 17, 2024 | ca.finance.yahoo.comLUNG Apr 2024 12.500 callMarch 16, 2024 | finanznachrichten.dePulmonx Corporation: Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 15, 2024 | globenewswire.comPulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | ca.finance.yahoo.comLUNG Apr 2024 7.500 putMarch 4, 2024 | ca.finance.yahoo.comLUNG May 2024 7.500 putMarch 3, 2024 | finance.yahoo.comLUNG Aug 2024 10.000 putMarch 3, 2024 | finance.yahoo.comLUNG Apr 2024 10.000 callMarch 3, 2024 | finance.yahoo.comLUNG Aug 2024 20.000 callMarch 1, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Bolsters Position in Pulmonx CorpSee More Headlines Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/05/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LUNG CUSIPN/A CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees279Year FoundedN/APrice Target and Rating Average Stock Price Target$16.33 High Stock Price Target$18.00 Low Stock Price Target$14.00 Potential Upside/Downside+66.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,840,000.00 Net Margins-80.46% Pretax Margin-87.76% Return on Equity-46.61% Return on Assets-31.69% Debt Debt-to-Equity Ratio0.30 Current Ratio6.50 Quick Ratio5.77 Sales & Book Value Annual Sales$68.68 million Price / Sales5.51 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book3.18Miscellaneous Outstanding Shares38,540,000Free Float36,340,000Market Cap$378.46 million OptionableOptionable Beta0.66 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David A. Lehman (Age 63)General Counsel & Secretary Comp: $651.39kMr. Geoffrey Beran Rose (Age 50)Chief Commercial Officer Comp: $632.29kMr. Steven S. Williamson (Age 51)CEO, President & Director Mr. Mehul Joshi (Age 63)Chief Financial Officer Mr. Sri RadhakrishnanChief Technical OfficerMs. Marcee M. Maroney (Age 54)Vice President of Marketing Sarah HuberVice President of Sales (U.S.)Ms. Lisa Paul (Age 60)Chief People Officer Mr. Jérôme ErathSenior VP & GM of Europe Middle-East & AfricaMr. John B. McKune (Age 48)VP & Corporate Controller More ExecutivesKey CompetitorsCerusNASDAQ:CERSLyra TherapeuticsNASDAQ:LYRASight SciencesNASDAQ:SGHTBioventusNYSE:BVSInovio PharmaceuticalsNASDAQ:INOView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 7,316 shares on 4/30/2024Ownership: 0.022%Geoffrey Beran RoseSold 1,184 sharesTotal: $8,868.16 ($7.49/share)Allspring Global Investments Holdings LLCBought 7,316 shares on 4/18/2024Ownership: 0.022%Geoffrey Beran RoseSold 1,184 sharesTotal: $11,082.24 ($9.36/share)Glendon E French IIISold 6,954 sharesTotal: $63,003.24 ($9.06/share)View All Insider TransactionsView All Institutional Transactions LUNG Stock Analysis - Frequently Asked Questions Should I buy or sell Pulmonx stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LUNG shares. View LUNG analyst ratings or view top-rated stocks. What is Pulmonx's stock price target for 2024? 6 analysts have issued twelve-month price targets for Pulmonx's shares. Their LUNG share price targets range from $14.00 to $18.00. On average, they anticipate the company's stock price to reach $16.33 in the next year. This suggests a possible upside of 66.3% from the stock's current price. View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts. How have LUNG shares performed in 2024? Pulmonx's stock was trading at $12.75 at the start of the year. Since then, LUNG shares have decreased by 23.0% and is now trading at $9.82. View the best growth stocks for 2024 here. Are investors shorting Pulmonx? Pulmonx saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,730,000 shares, an increase of 53.1% from the March 31st total of 1,130,000 shares. Based on an average daily volume of 557,800 shares, the days-to-cover ratio is presently 3.1 days. Currently, 5.0% of the company's stock are short sold. View Pulmonx's Short Interest. When is Pulmonx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our LUNG earnings forecast. How were Pulmonx's earnings last quarter? Pulmonx Co. (NASDAQ:LUNG) announced its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm earned $18.85 million during the quarter, compared to the consensus estimate of $17.54 million. Pulmonx had a negative net margin of 80.46% and a negative trailing twelve-month return on equity of 46.61%. During the same period in the prior year, the company posted ($0.42) EPS. What guidance has Pulmonx issued on next quarter's earnings? Pulmonx updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $81.0 million-$84.0 million, compared to the consensus revenue estimate of $82.2 million. When did Pulmonx IPO? Pulmonx (LUNG) raised $100 million in an IPO on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Pulmonx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.02%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, John Mckune, Richard Ferrari and Scientific Corp Boston. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LUNG) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmithWarren Buffet Stockpiling Gold?Reagan Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
